By 24 hours following start of combination therapy with pemetrexed plus cisplatin, tumor avidity for FLT began to fall below baseline, albeit not significantly, with a mean tumor FLTMAX of -6.0% (±10.5%, p = 0.35). Here, FLT1 is linked to neoplasm.